3 Branded and Generic Pharma Stocks With a Strong Future Roadmap: Mankind Pharma, Alkem Laboratories and Aurobindo Pharma

Branded and generic pharma stocks give investors exposure to drug makers that mix branded domestic sales with generic exports. Prescription growth, product mix and export approvals decide how steady earnings are.

This list covers three branded and generic pharma stocks: Mankind Pharma for branded formulations and consumer health, Alkem Laboratories for domestic brands and generic exports and Aurobindo Pharma for generic formulations and ingredients. Every figure comes from the latest reported financials and the 8 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Branded and Generic Pharma Stocks?

Branded and generic pharma stocks are shares of companies that make and sell branded medicines and generics in India and abroad. Results depend on prescription growth, export approvals and product mix, so product mix and approvals separate the stronger names.

Branded and Generic Pharma Stocks at a Glance

The table compares size, valuation, return on equity and debt for the three branded and generic pharma stocks as of the 8 Oct 2026 close.

Among drug maker stocks, Mankind Pharma trades at a premium to the industry P/E, while Alkem and Aurobindo Pharma trade at a discount.

Why Do Branded and Generic Pharma Stocks Have a Strong Roadmap in India?

Branded and generic pharma stocks have a strong roadmap in India because chronic disease cases are rising, insurance coverage is widening and global markets keep buying generics. Three drivers stand out.

• Chronic therapies: Long-term treatments give steady repeat prescriptions.
• Wider healthcare access: More insurance and clinics raise medicine use.
• Generic demand abroad: Exporters supply cost-effective medicines to global buyers.

Mankind Pharma: Branded Formulations Anchor the Roadmap

Mankind Pharma's roadmap rests on branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, with a broad brand portfolio supporting prescriptions and sales.

Revenue grew from Rs 7,977.58 crore in FY22 to Rs 14,636.43 crore in FY26, an 83.5% rise, and FY26 revenue was 14.8% higher than FY25. FY26 net profit fell 3.4% to Rs 1,938.10 crore. Over four years, net profit rose from Rs 1,452.96 crore in FY22 to Rs 1,938.10 crore. In Q1 FY27, revenue grew 11.7% to Rs 4,075.59 crore, and net profit rose 29.1% to Rs 574.09 crore. Operating margin was 27.06% in FY26 and 27.42% in Q1 FY27 against 26.04% a year earlier.

Debt to equity is 0.39 and return on equity is 11.74%. FY26 operating cash flow was Rs 3,121.29 crore against capital expenditure of Rs 737.24 crore. Mankind Pharma paid a dividend of Rs 1 per share for FY26, a yield of 0.04%. At a P/E of 47.91 against an industry P/E of 37.59, the stock trades above its industry multiple.

What to watch: FY26 net profit of Rs 1,938.10 Cr was lower than the Rs 2,006.59 Cr of FY25.

Alkem Laboratories: Domestic Brands and Generics Drive the Pipeline

Alkem's roadmap rests on branded generics in India along with generic exports and a presence in international markets, with a mix of domestic brands and exports supporting earnings.

Revenue grew from Rs 10,796.84 crore in FY22 to Rs 15,295.62 crore in FY26, a 41.7% rise, and FY26 revenue was 13.7% higher than FY25. FY26 net profit rose 6.2% to Rs 2,353.13 crore. Over four years, net profit rose from Rs 1,680.32 crore in FY22 to Rs 2,353.13 crore. In Q1 FY27, revenue grew 11.0% to Rs 3,892.90 crore, and net profit fell 22.0% to Rs 521.49 crore. Operating margin was 23.20% in FY26 and 24.57% in Q1 FY27 against 26.36% a year earlier.

Debt to equity is 0.15 and return on equity is 16.66%. FY26 operating cash flow was Rs 1,963.03 crore against capital expenditure of Rs 617.26 crore. Alkem paid a dividend of Rs 53 per share for FY26, a yield of 1.01%. At a P/E of 28.43 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: The Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier, and Q1 FY27 net profit was 22.0% lower than a year earlier.

Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg

Aurobindo Pharma's roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.

Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.

Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.

What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.

Best Branded and Generic Pharma Stocks in India: Mankind Pharma vs Alkem vs Aurobindo Pharma on Key Financials

Among the best branded and generic pharma stocks in India, Mankind Pharma leads on FY26 revenue growth and FY26 operating margin; Alkem leads on FY26 net profit growth and return on equity; Aurobindo Pharma leads on Q1 FY27 revenue growth and the lowest P/E. The table puts the numbers side by side.

Pharma earnings follow prescription growth, export approvals and product mix, so full-year numbers and quarterly trends together give a better view.

How to Evaluate Branded and Generic Pharma Stocks to Buy Before You Invest

A short checklist keeps the research consistent when you screen branded and generic pharma stocks and shortlist branded and generic pharma stocks to buy.

1. Compare each stock's P/E with its industry P/E, which is 37.59 for all three here.
2. Check the split between domestic and export sales, since each has different drivers.
3. Check whether revenue growth is turning into profit growth, not only sales.
4. Read operating cash flow against capital expenditure to see how growth is funded.
5. Watch debt to equity and interest cover before sizing a position.
6. Spread exposure across companies and business lines instead of one demand cycle.

Check the Univest Screener for live data on these branded and generic pharma stocks

Risks to Consider Before Investing in Branded and Generic Pharma Stocks

• Quarterly profit: Alkem's Q1 FY27 net profit was 22.0% lower than a year earlier.
• Annual profit: Mankind Pharma's FY26 net profit of Rs 1,938.10 Cr was lower than the Rs 2,006.59 Cr of FY25.
• Margins: Alkem's Q1 FY27 operating margin of 24.57% was below the 26.36% of a year earlier.
• Pricing controls: Price rules can limit growth in some medicines.

Download the Univest iOS App or Univest Android App to track Mankind Pharma, Alkem and Aurobindo Pharma live.

Final Take: Which Stock Has the Strongest Roadmap?

These three drug maker stocks cover branded formulations with consumer health, domestic brands with generics and generic formulations and ingredients. Mankind Pharma leads on FY26 revenue growth and FY26 operating margin; Alkem leads on FY26 net profit growth and return on equity; Aurobindo Pharma leads on Q1 FY27 revenue growth and the lowest P/E.

Across branded and generic pharma stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the branded and generic pharma stocks to buy discussed here.

FAQs on Branded and Generic Pharma Stocks

Which are the best branded and generic pharma stocks in India with a strong roadmap?

Ans. Mankind Pharma, Alkem Laboratories and Aurobindo Pharma stand out for their roadmaps in branded formulations with consumer health, domestic brands with generics and generic formulations and ingredients. FY26 revenue growth was 14.8% at Mankind Pharma, 13.7% at Alkem and 5.6% at Aurobindo Pharma, and return on equity ranges from 9.25% to 16.66%.

Is Mankind Pharma a good stock to buy now?

Ans. Mankind Pharma has a debt to equity ratio of 0.39, a return on equity of 11.74% and a P/E of 47.91 against an industry P/E of 37.59. Valuation, pricing rules and regulatory checks move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.

What is the P/E ratio of Mankind Pharma, Alkem and Aurobindo Pharma?

Ans. The P/E ratio is 47.91 for Mankind Pharma (industry 37.59), 28.43 for Alkem (industry 37.59) and 25.46 for Aurobindo Pharma (industry 37.59). Only Mankind Pharma trades at or above the industry multiple.

Which of these branded and generic pharma stocks has the highest return on equity?

Ans. Alkem Laboratories has the highest return on equity at 16.66%, followed by Mankind Pharma at 11.74% and Aurobindo Pharma at 9.25%.

What are the risks of investing in branded and generic pharma stocks?

Ans. The main risks are quarterly profit, annual profit, margins and pricing controls. Alkem's Q1 FY27 net profit was 22.0% lower than a year earlier.

How did Mankind Pharma, Alkem and Aurobindo Pharma perform in Q1 FY27?

Ans. Mankind Pharma reported revenue of Rs 4,075.59 crore, up 11.7% year on year, and net profit rose 29.1% to Rs 574.09 crore. Alkem Laboratories reported revenue of Rs 3,892.90 crore, up 11.0% year on year, and net profit fell 22.0% to Rs 521.49 crore. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore.

Do branded and generic pharma stocks pay dividends?

Ans. Yes, all three companies pay dividends. The dividend yield is 0.04% for Mankind Pharma, 1.01% for Alkem and 0.25% for Aurobindo Pharma, based on dividends declared for FY26.

How can I invest in branded and generic pharma stocks in India?

Ans. You can buy branded and generic pharma stocks through a demat and trading account on NSE or BSE after checking each company's financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.